Table 1.
Search results from the ClinicalTrials.gov database.
| ID | Condition | Intervention | Subject | Endpoint | Size | Results |
|---|---|---|---|---|---|---|
| NCT00023621 | BCC | Oral celecoxib | Patients with history of BCC | Rate of BCC | 60 | Celecoxib significantly reduced BCC number and burden [20]. |
| NCT00644384 | NMSC | Oral acitretin | With history of NMSC | Rate of new NMSC; surrogate biomarkers | 130 | No results published |
| NCT00003611 | NMSC | Oral acitretin | With history of skin cancers with organ transplantation | Rate of new NMSC; surrogate biomarkers | 70 | Acitretin showed benefit but not significant; the patients who received acitretin reported significantly more mucositis and skin toxicities compared to the patients who received placebo [21]. |
| NCT00007631 | NMSC | Topical tretinoin | With history of NMSC | Rate of NMSC | 1131 | High-dose topical tretinoin was ineffective at reducing risk of NMSC [22,23,24]. |
| NCT00847912 | NMSC | 5-FU topical | Veterans with history of NMSC | Rate of NMSC | 954 | Risk of SCC reduction was seen in the first year only; risk of BCC reduction in the first year was not significant [25]. |
| NCT00021294 | NMSC | Topical DFMO combined with triamcinolone | Patients with AK | Rate of NMSC | 102 | The low-dose topical drug interventions were effective in reducing skin biopsy nuclear abnormality [26]. |
| NCT00601640 | Other | DFMO combined with diclofenac | Individuals with skin sun damage | Nuclear marker | 156 | The addition of topical DFMO to topical diclofenac did not enhance its activity [27]. |
| NCT00204789 | Other | Oral DFMO | Organ transplant recipients | Safety; targets of DFMO | 52 | No significant effect for DFMO [28]; oral DFMO at 500 mg/m2/day was safe and tolerable and resulted in significant inhibition of phorbol ester-induced skin ODC activity [29]. |
| NCT01032343 | Skin immunity | Omega-3 polyunsaturated fatty acids (PUFA) | Healthy volunteers | Nickel contact hypersensitivity | 79 | Oral PUFAs abrogated photoimmunosuppression in human skin, providing additional support for their chemopreventive role [30]. |
| NCT01447355 | Other | Oral cholecalciferol (vitamin D) | Healthy subjects with insufficient serum levels of 25-hydroxyvitamine D | Changes in vitamin D receptor expression; skin differentiation biomarkers; safety and tolerability | 25 | High-dose cholecalciferol supplementation raised serum VD metabolite levels and CYP24 mRNA and caspase-14 levels in the skin [31]. |
| NCT00002811 | AK | Liposomal T4N5 lotion | Rate of AK | 30 | No results published | |
| NCT00089180 | NMSC | Liposomal T4N5 lotion | Renal transplant recipients with history of NMSC | Rate of NMSC | 100 | No results published |
| NCT03769285 | NMSC | Oral nicotinamide | Solid organ transplant recipients | Rate of NMSC | 120 | Ongoing |
| NCT04091022 | NMSC | Topical diclofenac and topical DFMO | With history of NMSC | Rate of NMSC | 138 | No results published |
| NCT02636569 | NMSC | Topical diclofenac | History of NMSC | Biomarkers in skin biopsies | 24 | No results published |
| NCT03210740 | NMSC | AM001 Cream (topical Potassium dobesilate) | Patients with AK | Clearance of AK | 30 | No results published |
| NCT02347813 | SCC | Oral pioglitazone | Patients with history of frequent occurrence of SCC | Rate of SCC | 12 | No results published |
|
NCT05159752 NCT05370235 |
Other | Afamelanotide | XP patients | Safety and efficacy on skin damage | 6 | Recruiting |
NMSC: non-melanoma skin cancer; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; AK: actinic keratosis; XP: Xeroderma pigmentosum; DFMO: difluoromethylornithine; PUFA: polyunsaturated fatty acid; 5-FU: 5-fluorouracil.